Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?

OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2011-06, Vol.34 (6), p.1424-1430
Hauptverfasser: Eckel, Robert H, Kahn, Steven E, Ferrannini, Ele, Goldfine, Allison B, Nathan, David M, Schwartz, Michael W, Smith, Robert J, Smith, Steven R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1430
container_issue 6
container_start_page 1424
container_title Diabetes care
container_volume 34
creator Eckel, Robert H
Kahn, Steven E
Ferrannini, Ele
Goldfine, Allison B
Nathan, David M
Schwartz, Michael W
Smith, Robert J
Smith, Steven R
description OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.
doi_str_mv 10.2337/dc11-0447
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3114323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A259679468</galeid><sourcerecordid>A259679468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</originalsourceid><addsrcrecordid>eNp90l2LEzEUBuAgilurF_4BHRBRL2bN12QSL5S1fi0s7oVbvAxnkjPdyDRTJ9OF-utNt3V1oUgIgZznZIaXQ8hjRo-5EPVr7xgrqZT1HTJhRlRlVUl9l0wok6asjOFH5EFKPyjNRuv75IgzRbkUbELm5w2mMG4KiL642Kyw4MWHAA2OmN4U3y9hLGYQi_dYzGNoA_preH3_FdGnYuy3xdPow1Xwa-jCL_TvHpJ7LXQJH-3PKZl_-ngx-1KenX8-nZ2cla5SaiwFqqppwNVSUEEV1UpxV4kWW4eycZICgpKG5hID0Ea1pvJeN5LT2mkmxZS83b27WjdL9A7jOEBnV0NYwrCxPQR7uxLDpV30V1aw3J2zm5IX-weG_uca02iXITnsOojYr5PVShtjqDFZvvyvZJQxTnOudabPdnQBHdoQ2z5_2225PeGVUbWRSmdVHlALjJh_tI_Yhnx9yx8f8Hl5XAZ3sOHVrsENfUoDtje5MGq3c2O3c2O3c5Ptk3-DvJF_BiWD53sAyUHXDhBdSH-dzEtTld3TnWuht7AYspl_y7lImjfXtRK_AcUPz3Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011201607</pqid></control><display><type>article</type><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R</creator><creatorcontrib>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R ; European Association for the Study of Diabetes ; American Diabetes Association ; Endocrine Society</creatorcontrib><description>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc11-0447</identifier><identifier>PMID: 21602431</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Animals ; Anti-Obesity Agents - therapeutic use ; attitudes and opinions ; Bariatric Surgery ; Behavior Therapy ; Biological and medical sciences ; blood glucose ; clinical trials ; cost effectiveness ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; drugs ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; experts ; genetics ; Humans ; Hypoglycemic Agents - therapeutic use ; insulin resistance ; Insulin Resistance - physiology ; Insulin-Secreting Cells - physiology ; lifestyle ; Medical sciences ; Metabolic diseases ; Miscellaneous ; noninsulin-dependent diabetes mellitus ; Obesity ; Obesity - complications ; Obesity - drug therapy ; Obesity - genetics ; Obesity - physiopathology ; pathogenesis ; pathophysiology ; patient care ; patients ; Pharmaceutical industry ; Prevention ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Reviews/Commentaries/ADA Statements ; Risk Factors ; Type 2 diabetes ; Weight Loss</subject><ispartof>Diabetes care, 2011-06, Vol.34 (6), p.1424-1430</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 American Diabetes Association</rights><rights>2011 by the American Diabetes Association and The Endocrine Society. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</citedby><cites>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,309,310,314,776,780,785,786,881,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24242806$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21602431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eckel, Robert H</creatorcontrib><creatorcontrib>Kahn, Steven E</creatorcontrib><creatorcontrib>Ferrannini, Ele</creatorcontrib><creatorcontrib>Goldfine, Allison B</creatorcontrib><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Schwartz, Michael W</creatorcontrib><creatorcontrib>Smith, Robert J</creatorcontrib><creatorcontrib>Smith, Steven R</creatorcontrib><creatorcontrib>European Association for the Study of Diabetes</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><creatorcontrib>Endocrine Society</creatorcontrib><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</description><subject>Animals</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>attitudes and opinions</subject><subject>Bariatric Surgery</subject><subject>Behavior Therapy</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>clinical trials</subject><subject>cost effectiveness</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>drugs</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>experts</subject><subject>genetics</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>insulin resistance</subject><subject>Insulin Resistance - physiology</subject><subject>Insulin-Secreting Cells - physiology</subject><subject>lifestyle</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>noninsulin-dependent diabetes mellitus</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - genetics</subject><subject>Obesity - physiopathology</subject><subject>pathogenesis</subject><subject>pathophysiology</subject><subject>patient care</subject><subject>patients</subject><subject>Pharmaceutical industry</subject><subject>Prevention</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Reviews/Commentaries/ADA Statements</subject><subject>Risk Factors</subject><subject>Type 2 diabetes</subject><subject>Weight Loss</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90l2LEzEUBuAgilurF_4BHRBRL2bN12QSL5S1fi0s7oVbvAxnkjPdyDRTJ9OF-utNt3V1oUgIgZznZIaXQ8hjRo-5EPVr7xgrqZT1HTJhRlRlVUl9l0wok6asjOFH5EFKPyjNRuv75IgzRbkUbELm5w2mMG4KiL642Kyw4MWHAA2OmN4U3y9hLGYQi_dYzGNoA_preH3_FdGnYuy3xdPow1Xwa-jCL_TvHpJ7LXQJH-3PKZl_-ngx-1KenX8-nZ2cla5SaiwFqqppwNVSUEEV1UpxV4kWW4eycZICgpKG5hID0Ea1pvJeN5LT2mkmxZS83b27WjdL9A7jOEBnV0NYwrCxPQR7uxLDpV30V1aw3J2zm5IX-weG_uca02iXITnsOojYr5PVShtjqDFZvvyvZJQxTnOudabPdnQBHdoQ2z5_2225PeGVUbWRSmdVHlALjJh_tI_Yhnx9yx8f8Hl5XAZ3sOHVrsENfUoDtje5MGq3c2O3c2O3c5Ptk3-DvJF_BiWD53sAyUHXDhBdSH-dzEtTld3TnWuht7AYspl_y7lImjfXtRK_AcUPz3Y</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Eckel, Robert H</creator><creator>Kahn, Steven E</creator><creator>Ferrannini, Ele</creator><creator>Goldfine, Allison B</creator><creator>Nathan, David M</creator><creator>Schwartz, Michael W</creator><creator>Smith, Robert J</creator><creator>Smith, Steven R</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110601</creationdate><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><author>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>attitudes and opinions</topic><topic>Bariatric Surgery</topic><topic>Behavior Therapy</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>clinical trials</topic><topic>cost effectiveness</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>drugs</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>experts</topic><topic>genetics</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>insulin resistance</topic><topic>Insulin Resistance - physiology</topic><topic>Insulin-Secreting Cells - physiology</topic><topic>lifestyle</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>noninsulin-dependent diabetes mellitus</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - genetics</topic><topic>Obesity - physiopathology</topic><topic>pathogenesis</topic><topic>pathophysiology</topic><topic>patient care</topic><topic>patients</topic><topic>Pharmaceutical industry</topic><topic>Prevention</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Reviews/Commentaries/ADA Statements</topic><topic>Risk Factors</topic><topic>Type 2 diabetes</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eckel, Robert H</creatorcontrib><creatorcontrib>Kahn, Steven E</creatorcontrib><creatorcontrib>Ferrannini, Ele</creatorcontrib><creatorcontrib>Goldfine, Allison B</creatorcontrib><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Schwartz, Michael W</creatorcontrib><creatorcontrib>Smith, Robert J</creatorcontrib><creatorcontrib>Smith, Steven R</creatorcontrib><creatorcontrib>European Association for the Study of Diabetes</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><creatorcontrib>Endocrine Society</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eckel, Robert H</au><au>Kahn, Steven E</au><au>Ferrannini, Ele</au><au>Goldfine, Allison B</au><au>Nathan, David M</au><au>Schwartz, Michael W</au><au>Smith, Robert J</au><au>Smith, Steven R</au><aucorp>European Association for the Study of Diabetes</aucorp><aucorp>American Diabetes Association</aucorp><aucorp>Endocrine Society</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>34</volume><issue>6</issue><spage>1424</spage><epage>1430</epage><pages>1424-1430</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>21602431</pmid><doi>10.2337/dc11-0447</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-5992
ispartof Diabetes care, 2011-06, Vol.34 (6), p.1424-1430
issn 0149-5992
1935-5548
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3114323
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Animals
Anti-Obesity Agents - therapeutic use
attitudes and opinions
Bariatric Surgery
Behavior Therapy
Biological and medical sciences
blood glucose
clinical trials
cost effectiveness
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - etiology
Diabetes Mellitus, Type 2 - genetics
Diabetes. Impaired glucose tolerance
drugs
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
experts
genetics
Humans
Hypoglycemic Agents - therapeutic use
insulin resistance
Insulin Resistance - physiology
Insulin-Secreting Cells - physiology
lifestyle
Medical sciences
Metabolic diseases
Miscellaneous
noninsulin-dependent diabetes mellitus
Obesity
Obesity - complications
Obesity - drug therapy
Obesity - genetics
Obesity - physiopathology
pathogenesis
pathophysiology
patient care
patients
Pharmaceutical industry
Prevention
Public health. Hygiene
Public health. Hygiene-occupational medicine
Reviews/Commentaries/ADA Statements
Risk Factors
Type 2 diabetes
Weight Loss
title Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T00%3A21%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Obesity%20and%20Type%202%20Diabetes:%20What%20Can%20Be%20Unified%20and%20What%20Needs%20to%20Be%20Individualized?&rft.jtitle=Diabetes%20care&rft.au=Eckel,%20Robert%20H&rft.aucorp=European%20Association%20for%20the%20Study%20of%20Diabetes&rft.date=2011-06-01&rft.volume=34&rft.issue=6&rft.spage=1424&rft.epage=1430&rft.pages=1424-1430&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc11-0447&rft_dat=%3Cgale_pubme%3EA259679468%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1011201607&rft_id=info:pmid/21602431&rft_galeid=A259679468&rfr_iscdi=true